Hyounggyoon Yoo
CHA University Bundang Medical Center(KR)CHA University(KR)
Publications by Year
Research Areas
Diabetes Treatment and Management, Helicobacter pylori-related gastroenterology studies, Gastroesophageal reflux and treatments, Pancreatic function and diabetes, Peptidase Inhibition and Analysis
Most-Cited Works
- → The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data(2022)32 cited
- → Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects(2019)23 cited
- → A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators(2020)15 cited
- → Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019(2021)11 cited
- → <p>Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects</p>(2020)8 cited
- → A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males(2024)6 cited
- → <p>Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects</p>(2020)6 cited
- → Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study(2022)5 cited
- → Standardization of the proceedings for preparing clinical trials of corneal xenotransplantation in South Korea(2018)5 cited
- → Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation(2023)5 cited